ArticleFrontiers in immunology2021
Safety of African Swine Fever Vaccine Candidate Lv17/WB/Rie1 in Wild Boar: Overdose and Repeated Doses.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- A dual-gene-deleted ASFV Lv17/WB/Rie1-ΔCD candidate administered orally to wild boar confers DIVA-compatible protection against virulent challenge.The veterinary quarterly · 2026Article
- Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence.Emerging microbes & infections · 2026Article
- Article
- Oral Bait Immunization of Eurasian Wild Boar (Vaccines · 2026Article
- First detection and characterization of a non-haemadsorbing African swine fever virus (genotype II) isolated from a wild boar in Russia.Frontiers in microbiology · 2026Article
- WiBISS: a tool to estimate avoided lost revenue of African swine fever wild boar vaccination at municipality level.Frontiers in veterinary science · 2025Article
- Viral Distribution of Wild Boar Exposed to Low (Vaccine Candidate) and High Virulence African Swine Fever Virus Isolates: Immunohistochemical Characterization.Transboundary and emerging diseases · 2025Article
- Tertiary lymphoid organs in wild boar exposed to a low-virulent isolate of African swine fever virus.The veterinary quarterly · 2024Article
- Article
- Recent progress and major gaps in the vaccine development for African swine fever.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Optimizing Vaccination Strategies against African Swine Fever Using Spatial Data from Wild Boars in Lithuania.Viruses · 2024Article
- Article
- Challenging boundaries: is cross-protection evaluation necessary for African swine fever vaccine development? A case of oral vaccination in wild boar.Frontiers in immunology · 2024Article
- The Effect of Partial and Temporary Vaccination on African Swine Fever Eradication Rates.Transboundary and emerging diseases · 2024Article
- The Production of Recombinant African Swine Fever Virus Lv17/WB/Rie1 Strains and Their In Vitro and In Vivo Characterizations.Vaccines · 2023Article
- Article
- Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence.Vaccines · 2023Article
- Low transmission risk of African swine fever virus between wild boar infected by an attenuated isolate and susceptible domestic pigs.Frontiers in veterinary science · 2023Article
- Vaccines for African swine fever: an update.Frontiers in microbiology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a highly lethal infectious disease that affects domestic pigs and wild boar. Outbreaks of ASF have grown considerably in the last decade causing important economic consequences for the swine industry. Its control is hampered by the lack of an effective treatment or vaccine. In Europe, the wild boar is a key wild reservoir for ASF. The results of the oral vaccination trial of wild boar with Lv17/WB/Rie1 are hope for this problem. However, this vaccine candidate has certain safety concerns, since it is a naturally attenuated vaccine. Therefore, the current study aims to evaluate the safety of this vaccine candidate in terms of overdose (high dose) and repeated doses (revaccination) in wild boar. Low-dose orally vaccinated animals developed only a slight transient fever after vaccination and revaccination. This was also the case for most of the high-dose vaccinated wild boar, except for one of them which succumbed after revaccination. Although this fatality was related to hierarchical fights between animals, we consider that further studies are required for clarification. Considering these new results and the current epidemiological situation of ASF in wild boar, this vaccine prototype is a promising tool for the control of the disease in these wild populations, although further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.